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Abstract
Each year, pediatric traumatic brain injury (TBI) accounts for 435,000 emergency department visits,
37,000 hospital admissions, and approximately 2,500 deaths in the United States. TBI results in
immediate injury from direct mechanical force and shear. Secondary injury results from the release
of biochemical or inflammatory factors that alter the loco-regional milieu in the acute, subacute, and
delayed intervals after a mechanical insult. Preliminary preclinical and clinical research is underway
to evaluate the benefit from progenitor cell therapeutics, hypertonic saline infusion, and controlled
hypothermia. However, all phase III clinical trials investigating pharmacologic monotherapy for TBI
have shown no benefit. A recent National Institutes of Health consensus statement recommends
research into multimodality treatments for TBI. This article will review the complex pathophysiology
of TBI as well as the possible therapeutic mechanisms of progenitor cell transplantation, hypertonic
saline infusion, and controlled hypothermia for possible utilization in multimodality clinical trials.
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Each year, pediatric traumatic brain injury (TBI) accounts for 435,000 emergency department
visits, 37,000 hospital admissions, and approximately 2,500 deaths in the United States.1 The
incidence of TBI-related hospitalization is 679 of 100,000 children.2 Of those patients affected,
up to 48% are impaired by physical, cognitive, and psychosocial deficits.3 Beginning
aggressive rehabilitation early in the patient’s hospital course has shown improvement in
functional status4,5; however, neurons show little ability to repair and no treatment modality
is currently available to reverse acute brain injury. A large body of work has pursued
pharmacologic neuroprotective strategies. Single agent pharmacologic neuroprotective
approaches to treat TBI have not proven successful clinically. Both clinical and preclinical
research is underway to show possible benefit from progenitor cell therapeutics, hypertonic
saline (HTS) treatment of intracranial hypertension, and controlled hypothermia for treatment
of TBI in the acute setting.
TBI Classification
The development of neuroprotective treatments for TBI requires a clear classification of injury
severity and understanding of pathophysiologic mechanisms. A common method of
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classification separates immediate (primary) injury from delayed (secondary) injury. Primary
injury results from direct mechanical force that leads to compression and shearing of neural,
glial, and vascular cells.6 A central core of cellular necrosis is surrounded by a diffuse area of
axonal cell injury (penumbra). Secondary injury consists of the delayed deleterious effects
resulting from the release of biochemical or inflammatory factors that alter the loco-regional
milieu in the acute, subacute, and delayed intervals after a mechanical insult.
A recent consensus statement from the Society of Neurotrauma classified TBI according to
acute clinical monitoring, pathoanatomic injury, neuroimaging, and biomarkers. The Glasgow
Coma Scale (GCS) is used to clinically classify TBI as mild, moderate, or severe. Although
useful in the acute phase (0–4 hours), GCS scores are often altered by the use of sedatives. In
addition, severe injury as indicated by GCS scoring fails to correlate with a specific mechanism
or neuropathology. Therefore, additional modalities such as high-resolution computed
tomography (CT), intracranial pressure (ICP) measurement, and magnetic resonance imaging
can be used to further classify TBI in the acute setting.7
TBI can be further classified using pathoanatomic injury types. Multiple in vivo models have
been developed to investigate the biomechanics of TBI allowing for the development of novel
neuroprotective therapies. Animal models include direct injury, acceleration-deceleration
injury, and impact injury. Table 1 outlines the advantages and disadvantages of each injury
model.8 The efficacy of many neuroprotective therapeutics developed in animal models has
been limited in human trials. A common thought is that the pathophysiology of injury in the
lissencephalic rat brain used in most models does not translate to the biomechanics of human
TBI. However, in vivo models continue to give insight into anatomic location of injury, cell
types at risk, and injury progression allowing for the investigation of novel therapies.7
Neuroimaging offers additional information for TBI classification that is independent of the
level of consciousness. Advantages of high-resolution CT include wide scale availability, short
testing time, and ability to detect mass effect, cerebral contusion, and hemorrage reliably.7
Magnetic resonance imaging is used to detect diffuse or traumatic axonal injury that is often
not appreciated on CT in the subacute time frame.9 When combined with an accurate clinical
assessment, neuroimaging is a powerful tool for TBI classification and the initiation of
therapeutic intervention.
Serum and cerebrospinal fluid (CSF) biomarker concentrations offer a theoretical method to
classify TBI severity and add a biological correlate to the loss of consciousness and imaging
potentially allowing for serial measurements and risk stratification. Recent clinical trials have
shown increased levels of serum myelin basic protein, neuron specific enolase, and the
biomarker S100B after TBI in a pediatric population.10,11 However, at the time of this review,
no published data were available to compare the efficacy of myelin basic protein, neuron
specific enolase, and S100B as biomarkers for TBI. Initial research has shown that biomarkers
could aid in the classification of TBI severity, but further investigation into the role of specific
markers needs to be completed.
Astute clinical assessment combined with neuroimaging, measurement of biomarkers, and
further investigation into pathoanatomic injury enables clinicians to initially measure the
severity of TBI and stratify patients according to risk. Classification of TBI directs patients to
the most effective therapeutic groups and allows the development of further clinical trials
investigating novel neuroprotective therapies.
TBI Pathophysiology: Implications for Future Targets
When compared with adults, the pediatric population is more susceptible to severe TBI because
of a more pliable and immature skull, weak cervical musculature, and proportionally increased
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head mass.12 After the primary mechanical insult, changes in the nervous system
microenvironment such as increased membrane permeability and calcium concentration,
formation of edema, decreased cerebral blood flow (CBF), increase in oxidative species, and
enhanced levels of inflammation could account for significant secondary injury. Figure 1
outlines the timing of cytokine formation, cerebral edema formation, scar formation, and
delayed neuronal death after TBI.
Post-Injury Neural Exitotoxicity
A large amount of preclinical research has linked neuronal cell excitotoxicity and elevated
extracellular glutamate with increased cellular membrane permeability and subsequent
neuronal injury. After TBI, elevated levels of excitatory amino acids, such as glutamate, have
been found in both animal and human models.13,14 Increased glutamate levels lead to neuronal
exitotoxicity and alteration of normal cellular metabolism. Previous work done in the
Robertson laboratory using a rat TBI model showed elevated lactate or creatinine ratios
consistent with increased glycolysis and decreased oxidative metabolism for as long as 7 days
after injury.15 In addition, [18F]fluorodeoxyglucose-positron emission tomography of human
patients after TBI has shown both regional and diffuse cerebral hyperglycolysis.16
The reliance of neuronal cells on anaerobic respiration depletes adenosine triphosphate (ATP)
stores leading to active ion pump failure. The loss of electrochemical equilibrium supplied by
the active Na+ or K+ pump and activation of ion channels by increased glutamate leads to
massive Ca2+ influx.17 Elevation of intracellular calcium has been shown to induce calpain-
mediated spectrin proteolysis causing increased levels of membrane breakdown and axonal
injury.18
The complex interactions between metabolism, glutamate, and membrane permeability offer
many targets for neuroprotection. Controlled hypothermia has been shown to slow metabolism
and decrease ATP utilization (discussed later).19,20 Additional research has shown improved
neurologic severity score as well as decreased brain edema and neuronal injury after infusion
of glutamate receptor antaganonists.21 Ideally, maintenance of the normal metabolic rate and
antagonism of glutamate channels could preserve the electrochemical gradient leading to
retained membrane integrity and decreased levels of calpain-induced axonal injury.
Cerebral Edema
Neuronal injury after TBI is largely mediated by increased ICP. Elevated ICP results from
increased brain tissue water derived from vasogenic and cytotoxic edema.22 Vasogenic edema
is due to uncontrolled ion and protein flux from the intravascular to extracellular space due to
disruption of the cerebral vascular endothelial cell lining.23 Work completed in the Halley lab
has shown vacuole formation in cerebral endothelial cell lining leading to breakdown of the
blood brain barrier causing increased transvascular protein flux and vasogenic interstitial
edema.17,24
As previously discussed, TBI is associated with active ion pump failure and increased
membrane permeability leading to elevation of intracellular ions. Influx of such ions leads to
the development of an osmotic gradient causing concurrent flow of water into the intracellular
space. The increase in intracellular water termed cytotoxic edema may be independent of
endothelial cell integrity.17
Increased ICP derived from vasogenic and cytotoxic edema is indirectly related to CBF.
Investigation of comatose patients after TBI with xenon-enhanced CT has shown decreased
CBF.25 In addition, clinically significant cerebral vasospasm leading to decreased CBF has
also been noted for up to 13 days in patients with severe TBI.26
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The relationships between increased ICP, CBF, and cerebral vasospasm yield possible
opportunities for neuroprotection. HTS infusion has been shown to decrease ICP while
augmenting mean arterial pressures leading to an increase in CBF (discussed later).27-29
Maintenance of cerebral perfusion pressure by controlling ICP and vasospasm could
significantly decrease neuronal cell injury.
Mitochondrial Injury
A common hypothesis implicates the role of mitochondrial oxidative damage in neuronal cell
death. Analysis of murine hippocampal mitochondria after controlled cortical impact (CCI)
injury showed increased protein oxidation and lipid peroxidation. Reactive nitrogen species
played a significant role in oxidation as evidenced by elevated levels of mitochondrial 3-
nitrotyrosine.30 The Hall laboratory investigated the role of peroxynitrite radicals on
mitochondrial respiration. The peroxynitrite donor SIN-1 (3-morpholinosydnonimine) was
administered to brain mitochondria showing a decrease in respiratory control ratio and increase
in oxidation. In addition, penicillamine, a peroxynitrite scavenging agent, and tempol, a free
radical scavenger, were shown to protect against oxidative damage.31 The generation of
oxidative radicals associated with TBI leads to increased secondary neuronal injury making
investigation into additional anti-oxidant treatments key for enhanced neuroprotection.
Neuronal Inflammation
TBI initiates an array of inflammatory cascades that contribute to secondary neuronal cell
injury. In vivo analysis of rat intracerebral fluid after CCI has shown elevation of the pro-
inflammatory cytokines TNFα, IL-1α, IL-1β, and IL-632 (Fig. 2). Further investigation of
human CSF after TBI has shown increased levels of the cytokines IL-1β, IL-6, IL-8, IL-10,
and TNFα as well as intracellular adhesion molecule 1 (ICAM-1) when compared with plasma.
33-36 To test this hypothesis, the Wainwright laboratory administered the experimental
therapeutic agent, Minozac (Mzc), to mice after CCI to decrease glial activation and
proinflammatory cytokine production. The results demonstrated that the attenuation of
cytokine production was associated with decreased astrocytic activation and improved
functional neurologic outcomes.37 Investigation into the administration of N-acetylcysteine
has shown attenuation of IL-1β, ICAM-1, and TNFα levels as well as reduction in blood brain
barrier permeability, apoptotic index, and cerebral edema when given within 1 hour of injury.
33,38 Modulation of the inflammatory response could significantly decrease neuronal injury
making further research into anti-inflammatory therapeutics imperative.
TREATMENT MODALITIES
Hypothermia
Clinical Significance—Controlled hypothermia after TBI could offer neuroprotection by
decreasing neuronal metabolism. Cerebral hypoperfusion and subsequent ischemia evident
during cardiovascular surgery or arrest provides a model for comparison with TBI. Controlled
hypothermia with cardiopulmonary bypass and hypothermic circulatory arrest during pediatric
cardiovascular surgery has shown a clear time dependent neuroprotective effect. In addition,
clinical trials investigating the effect of controlled hypothermia on adult cardiac arrest patients
showed decreased mortality (41 vs. 55%) and improved neurologic functional status.39 The
observed benefit of hypothermia in cardiac patients has led to multiple studies involving TBI.
A recent meta-analysis using eight clinical trials of controlled hypothermia in TBI showed a
significant decrease in mortality and improvement in neurologic function.40 The role of
hypothermia in the treatment of TBI remains controversial requiring further research into
possible therapeutic mechanisms with particular emphasis on examining the therapeutic
window.
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Possible Therapeutic Mechanisms—Controlled hypothermia is believed to decrease
neuronal metabolic rate after TBI. Although trials investigating the clinical effect of
hypothermia for treatment of TBI have been completed, the majority of basic science analysis
has been based on cardiac arrest models. In vivo research by the Griepp laboratory, measured
CBF as well as venous and arterial oxygen saturations during human hypothermic circulatory
arrest to calculate a temperature coefficient that was used to compare a distinct metabolic rate
separated by 10°C. Their results showed a significant decrease in metabolic rate associated
with hypothermia.20 An in vivo hypothermic piglet cardiac arrest model showed decreased
cerebral ATP utilization and acidosis in association with attenuation of the metabolic rate.19,
41 A growing body of preclinical and clinical research has given insight into the effect of
hypothermia on neuronal metabolism in arrest models; however, more investigation involving
TBI needs to be conducted to derive optimal strategies to enhance the therapeutic benefit.
TBI is associated with increased levels of extracellular glutamate and neuronal excitotoxicity.
13,14 The observed alteration in normal membrane electrochemistry and glutamate activated
ion channels increase intracellular calcium thereby stimulating calpain mediated neuronal
injury.18,42 Investigation into the effect of controlled hypothermia in rat global cerebral
ischemia models has shown decreased calpain activation and glutamate levels.43,44 Reduction
of calpain activation could decrease the neuronal apoptotic fraction while depressed function
of glutamate, activated ion channels, would stabilize the membrane electrochemical gradient
leading to a therapeutic benefit of controlled hypothermia.
Preclinical research studies have shown elevated levels of oxidative radicals associated with
TBI.30 Observation of rats undergoing cerebral ischemia-reperfusion injury found no increase
in oxidative radicals when maintained at hypothermic temperatures compared with a dramatic,
2.5 fold increase noted in normothermic controls.45 Further investigation of cerebral ischemia-
reperfusion injury in gerbils treated with controlled hypothermia has shown decreased H2O2
levels.46 Neuroprotection by controlled hypothermia seems to be partially mediated by the
reduction in oxidative radicals. Further research into treatment of TBI with hypothermia and
free radical scavengers such as tempol (BIOMOL International) could provide an additive
effect ultimately enhancing the neuroprotective effect.
TBI stimulates multiple inflammatory cascades leading to the increase in pro-inflammatory
and anti-inflammatory cytokines such as IL-1β, IL-6, IL-8, IL-10, TNFα, and ICAM-1.33-36
Significant increase in pro-inflammatory cytokines could lead to neuronal injury making
modulation of the inflammatory response a target for neuroprotective therapy. Preclinical
research has shown treatment with controlled hypothermia to decrease levels of ICAM-1
thereby attenuating neutrophil migration.47 However, analysis of CSF from children after TBI
showed no change in cytokine production after treatment with controlled hypothermia.48
Overall, the effect of hypothermia on inflammatory modulation remains controversial and
further investigation using both preclinical and clinical models needs to be completed.
Barriers to Treatment—The development of further clinical trials investigating the role of
controlled hypothermia in treatment of TBI requires careful assessment of the possible
untoward effects. A recent phase II clinical trial of moderate hypothermia after severe TBI has
shown no statistical difference in coagulopathy, arrythmias, or infectious complications in a
pediatric population.49 In addition, the timing of hypothermic treatment needs to be evaluated.
Review of current literature shows average initiation of therapy within 24 hours of TBI
followed by up to 48 hours of treatment; however, no trials exist comparing multiple treatment
timing parameters.
A recent meta-analysis of eight clinical trials investigating adult TBI showed statistically
significant reduced mortality (relative risk, 0.51) and improved neurologic outcome (relative
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risk, 1.91) in patients treated with moderate hypothermia for greater then 48 hours. However,
a significant increase in pneumonia (relative risk, 2.37) was also noted.40 Although still
controversial, prolonged hypothermia (greater than 48 hours) offers a promising treatment to
attenuate neuronal injury after TBI requiring further research into therapeutic safety and usage
as a multimodality treatment.
Hypertonic Saline
Clinical Significance—Previous research has shown that HTS infusion after TBI offers
neuroprotection via reduction of increased ICP leading to improved CBF.29,50 HTS
resuscitation also increased mean arterial pressures thereby attenuating a significant increase
of poor neurologic outcomes seen with hypotension within 6 hours of TBI.51 HTS infusion
decreased the complications, required interventions, and length of intensive care unit stay after
TBI in a pediatric population.52 Despite the promising results noted in the acute and subacute
setting, some trials have failed to show improved neurologic outcomes 6 months after TBI.
53 To organize further clinical trials and optimize the therapeutic efficacy of HTS resuscitation,
research into the role of HTS in control of ICP, maintenance of membrane electrochemical
potential, and modulation of the inflammatory response needs to be completed.
Possible Therapeutic Mechanisms—HTS reduces ICP by increasing the plasma
osmolarity (largely Na+) thereby reducing the flow of water into the intracellular and interstitial
spaces. Neuronal injury associated with TBI leads to accumulation of organic osmolytes within
the cell.54 Subsequent hyperosmolarity and influx of water is associated with increased brain
edema and ICP.55 HTS resuscitation increases the serum osmolarity reducing the flow of water
from the intravascular space into the extracellular space to attenuate the accumulation of brain
edema.29 In addition, HTS infusions increase intravascular volume28 leading to increased CBF.
27 The overall increase in CSF with decreased ICP leads to improved neuronal oxygenation
with reduction of ischemia.
TBI is associated with elevated levels of glutamate and Ca2+ as well as failure of active ion
pumps leading to disruption of the normal electrochemical gradient. HTS infusion increases
plasma sodium levels restoring normal function of the Na+ or glutamate pump thereby reducing
levels of extracellular glutamate.56 Normalization of intracellular Na+ leads to activation of
the Na+ or Ca2+ pump decreasing levels of intracellular Ca2+.57 Work completed in the Zaaroor
laboratory has shown decreased calpain activity in rats resuscitated with HTS after cortical
injury.58 Normalization of the membrane electrochemical gradient ultimately leading to
decreased calpain activated neuronal damage could account for the neuroprotection see with
HTS resuscitation.
TBI is associated with increased systemic inflammation and leukocyte migration leading to
secondary neuronal injury.33-36 In vivo, HTS infusion has shown decreased penumbral
neutrophil density after CCI in a rat model.58 A recent trial of HTS infusion in TBI patients
has also shown attenuation of tissue ICAM-1 and mitogen-activated protein kinase leading to
decreased neutrophil migration and neuronal apoptosis. In addition, a significant decrease in
multi organ dysfunction was observed.59 Preliminary research has shown benefit from HTS
resuscitation through modulation of neutrophil migration; however, further investigation into
the effect on the overall pro inflammatory response has yet to be completed.
Barriers to Treatment—Mannitol infusion has long been the standard of care for elevated
ICPs in the setting of TBI; however, because of increasing knowledge of cerebral physiology,
multiple in vivo trials have been completed to compare HTS to mannitol.60 Single, equi-
osmolar bolus doses of HTS and mannitol infused after TBI in a rat model showed significant
reduction in ICP for up to 500 minutes after treatment in the HTS group. Conversely, after a
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transient decrease in ICP, the mannitol group was found to return to or overshoot the baseline-
elevated ICP.61 In addition, HTS infusion after TBI in a rat model has shown significant
decrease in calpain-mediated apoptosis and neuroinflammation compared with a mannitol
treatment group. Of note, the additional benefit of HTS when compared with mannitol was
independent of the infused volume indicating a likely mechanism separate from the effect on
brain tissue edema.58 Initial in vivo research has shown the additional benefit from HTS therapy
for TBI; however, before acceptance as standard of care, prospective randomized trials with
comparison to mannitol will likely be needed.
Central pontine myelinolysis is a demyelinating disease of the pons that has been associated
with rapid changes in serum Na+ levels.62 It is believed that HTS resuscitation with TBI could
rapidly increase serum Na+ causing central pontine myelinolysis; however, small clinical trials
have shown no evidence of demyelination disorders.29
HTS resuscitation has been linked to increased rates of renal failure in burn patients63 with
evidence of reversible renal insufficiency in a pediatric TBI resuscitation trial.29 Pleural
effusions of unknown etiology have also been observed.64 HTS resuscitation after hypertensive
intracerebral hemorrhage has shown rebound malignant cerebral edema after 24 hours of
therapy.65 Although a review of the literature has shown some untoward effects from HTS
resuscitation, the observed therapeutic benefit seems to outweigh the potential risks.
Cell Therapy
Clinical Significance—A large amount of research is currently underway investigating the
role of cell therapeutics in the treatment of TBI. By definition, stem or progenitor cells are
capable of self-renewal and are multipotent meaning the cells are able to differentiate into
multiple cell lines.66 Progenitor cell populations are maintained in niches throughout the body
to protect against cell depletion or over proliferation.67 Adult stem cell niches and respective
populations currently under investigation include bone marrow-derived cells (mesenchymal
stem cells [MSCs] and hematopoeitic stem cells), subventricular zone (neural stem cells),
umbilical cord blood mononuclear fraction (MSCs and hematopoeitc stem cells), and adipose
tissue. Progenitor cell capacity to self-renew, multipotency, and ready availability make them
an attractive treatment modality for multiple diseases.
Preclinical studies evaluating the efficacy of stem cell therapeutics are in their infancy;
however, many promising results have already been published. Intravenous and direct
transplantation of MSCs, human umbilical cord blood, neural stem cells, and adipose-derived
stem cells after TBI in animal models have shown cell engraftment and functional neurologic
improvement.68-71 The development of clinical models requires careful investigation into
therapeutic mechanisms including transdifferentiation, growth factor secretion, cell to cell
contact, and modulation of the inflammatory response.
Possible Therapeutic Mechanisms—Initial preclinical research into cell therapeutics for
TBI has shown clear functional neurologic improvement, however, the exact mechanisms of
action have yet to be clearly delineated. Tissue specific stem cells such as MSCs have shown
the ability to differentiate into loco-regional cell lines and promote tissue regeneration.72 In
addition, MSCs have been shown to phenotypically adopt neural characteristics.73 Early
thought indicated such cell plasticity and engraftment could account for the observed
therapeutic benefit. However, the frequency of engraftment and clinical significance of
transdifferentiation remains controversial.74
Additional investigation has shown progenitor cell migration to the site of injury and secretion
of various trophic factors. Culture of MSCs with rat brain supernatant after CCI injury and
induced middle cerebral artery stroke have shown secretion of brain-derived neurotrophic
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factor, nerve growth factor, epidermal growth factor, hepatocyte growth factor, vascular
endothelial growth factor, insulin-like growth factor (IGF-1), and fibroblast growth factor
(FGF-2).75,76 Increased vascular endothelial growth factor levels have been shown to increase
penumbral angiogenesis in a rat stroke model.77 Progenitor cell secretion of growth factors
could alter the local neuronal cellular milieu stimulating resident cell regeneration or repair
accounting for the observed therapeutic benefit.
Cell-to-cell contact or fusion allowing transfer of proteins or genes is another theoretical
mechanism accounting for the efficacy of cell therapeutics. Preliminary investigation of heat
shocked epithelial airway cells treated with MSCs has shown 1% incidence of cellular fusion.
78 Current research to investigate the usage of progenitor cells as vehicles to carry deficient
genes that could be transferred via direct cellular contact is underway.79
As previously discussed, induction of a systemic inflammatory response plays a significant
role in secondary injury with TBI. A large amount of preclinical work has shown a decrease
in inflammation after treatment with progenitor cells in both in vivo and in vitro models. Culture
of MSCs with purified immune cells has shown an increase in the anti-inflammatory cytokines
IL-4 and IL-10 while decreasing levels of TNF-α and IFN-γ. Increased levels of IL-4 in
accordance with decreaed INF-γ has been shown to cause a shift from cytotoxic TH1 cells to
TH2 helper T cells. In addition, decreased TNF-α with increased IL-10 promotes a more tolerant
or anti-inflammatory immune response.80 In addition, transfusion of human umbilical cord
blood in rats after induced ischemic stroke prevented loss of splenic mass and a decrease in
CD8+ T cells that had previously been observed. Of note, overall T cell proliferation was
decreased in accordance with decreased INF-γ and increased IL-10 levels. An 85% reduction
in cerebral infarct volume was noted.81 Modulation of the systemic inflammatory response
offers a possible explanation for the therapeutic benefit of cell therapeutics and is an attractive
avenue for neuroprotection.
Barriers to Treatment—Both emboli and tumor development have been associated with
progenitor cell transplantation. MSC transplantation in a murine model has shown malignant
transformation into fibrosarcomas82 and osteosarcomas located in the lung.83 In addition,
pulmonary thromboemboli have been reported with intravenous transfusion of progenitor cells.
84 Intracarotid transfusion of progenitor cells in a stroke model has been associated with
decreased CBF.85 Overall, progenitor cell therapeutics offers exciting new therapies to enhance
neuroprotection; however, further research into cell delivery, treatment dosage, and timing of
therapy need completed before multi-center clinical trials.
Future considerations—The National Institutes of Health (NIH) recently convened a
meeting to discuss the future investigation of TBI therapeutics.86 The conference noted the
complex nature to neuronal injury and failure of all clinical trials based on monotherapy to
date. Recommendations included the development of in vitro models to research multimodality
treatments ultimately leading to preclinical and clinical selection of therapies that could have
an additive effect by targeting multiple mechanisms of TBI’s complex pathophysiology
(www.nih.gov).
TBI is a major source of morbidity and mortality in the American health system. Although
previous clinical and preclinical research has shown therapeutic benefit from controlled
hypothermia, HTS resuscitation, and cell therapeutics, multimodal therapy could potentially
offer the most effective treatment. The beneficial effects of hypothermia, HTS resuscitation,
and cell therapeutics could prove to be synergistic enhancing overall neuroprotection.
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Figure 1.
Timing in days of cytokine production, cerebral edema, scar formation, and delay cell death
after TBI.
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Figure 2.
Elevated intracerebral cytokines identified in specific areas and at specified time points relative
to the TBI. The pro-inflammatory cytokines IL-1α (A), IL-1β (B), IL-6 (C), and TNF-α (D)
were significantly elevated six hours after CCI in the injury and penumbral regions when
compared to sham animals (*p < 0.01 for all). IL-1α, IL-1β, and IL-6 remained elevated through
12, 12, and 24 hrs, respectively (*p < 0.01 or †p < 0.05). In the frontal area, IL-6 was
significantly increased at 24 hours (33–50 fold, p < 0.01, Dunnett’s test), but not at 6 or 12
hours after. TBI Reprinted with permission.32
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